

17 April 2024

**Privatisation by way of scheme of arrangement**

**Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited**

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

<b>Party</b>	<b>Date</b>	<b>Purchase / Sale</b>	<b>Number of shares</b>	<b>Price per share</b>	<b>Resultant balance (including those of any person with whom there is an agreement or understanding)</b>	<b>Percentage of class (including those of any person with whom there is an agreement or understanding)</b>
Peter Shao Chihwen	5 April 2024	Purchase	48,750	\$0.0000	80,831	0.0129%

End

Note:

Peter Shao Chihwen is a Class (3) associate connected with the Offeree company.

Dealings were made for his own account.

On 5 April 2024, 48,750 share awards were vested on Peter Shao Chihwen pursuant to the Post-IPO RSU Plan adopted by the Company.

This form was received by the Executive on 17 April 2024.